Galera Reports Third Quarter 2022 Financial Results and

Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 One-year ROMAN follow-up data presented at 2022 American Society for Radiation...

Related Keywords

United States ,Mel Sorensen ,Eugenep Kennedy ,Jont Holmlund ,Exchange Commission ,American Society For Radiation Oncology ,Hepatobiliary Surgery At Thomas Jefferson University ,Drug Administration ,Galera Therapeutics Inc ,Nasdaq ,Radiation Oncology ,Annual Meeting ,New Drug Application ,Induced Toxicity Programs ,Oral Mucositis ,Cancer Programs ,Advanced Pancreatic Cancer ,Small Cell Lung Cancer ,Corporate Updates ,Chief Medical ,Johns Hopkins Trained ,Hepatobiliary Surgery ,Thomas Jefferson University ,Private Securities Litigation Reform Act ,Breakthrough Therapy Designation ,Fast Track Designation ,Nasdaq Global Market ,Annual Report ,Quarterly Report ,Months Ended September ,Nasdaq Grtx ,Galera Therapeutics ,